Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AERAS-404 in Healthy Adults
NCT02109874Phase 1Completed
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Dec 2008
- Primary completion
- Dec 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of H4:IC31 in Tuberculosis (TB) (5 arms), sponsored by Aeras Global Vaccine Foundation. Primary endpoint: Number and severity of Serious Adverse Events (SAEs) at Day 182. Started Dec 2008; status: completed.
02
Drugs
H4:IC31
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02109874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109874.